Wednesday, 18 July 2018

Adlai Nortye acquires global rights to Novartis cancer drug

11 July 2018 | News

Adlai Nortye will have exclusive development and commercialization rights to buparlisib worldwide for all the therapeutic, prophylactic and/or diagnostic uses in humans.

Image credit- bnpparibasmf.in

Image credit- bnpparibasmf.in

China based Adlai Nortye Biopharma Co., Ltd., a biopharmaceutical company dedicated to discovering and commercializing new drugs in the field of oncology/immuno-oncology, has announced that it has entered into a Global License Agreement with Novartis Pharma AG, a global pharmaceutical company.

Under the terms of the Agreement, except for certain rights maintained by Novartis Pharma AG, Adlai Nortye will have exclusive development and commercialization rights to buparlisib worldwide for all the therapeutic, prophylactic and/or diagnostic uses in humans.

Buparlisib (BKM120) is an oral pan-PI3K inhibitor that targets all class 1 PI3K isoforms and is active in both hematologic malignancies and solid tumors. It has shown promising efficacy in combination with paclitaxel in head and neck squamous cell carcinoma (HNSCC) and has received a Fast-Track designation from the FDA.

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account

Survey Box

Has Health Care in Asia outpaced inflation?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls